These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

897 related articles for article (PubMed ID: 35216678)

  • 1. CD8
    Liao P; Wang W; Wang W; Kryczek I; Li X; Bian Y; Sell A; Wei S; Grove S; Johnson JK; Kennedy PD; Gijón M; Shah YM; Zou W
    Cancer Cell; 2022 Apr; 40(4):365-378.e6. PubMed ID: 35216678
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CD8
    Friedmann Angeli JP; Xavier da Silva TN; Schilling B
    Cancer Cell; 2022 Apr; 40(4):346-348. PubMed ID: 35334204
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pro-ferroptotic fatty acid metabolism renders cancer cells immunogenic.
    Kepp O; Kroemer G
    Trends Cancer; 2022 Oct; 8(10):785-787. PubMed ID: 35469799
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ACSL4-Mediated Ferroptosis and Its Potential Role in Central Nervous System Diseases and Injuries.
    Jia B; Li J; Song Y; Luo C
    Int J Mol Sci; 2023 Jun; 24(12):. PubMed ID: 37373168
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multi-enzyme Co-expressed Dual-Atom Nanozymes Induce Cascade Immunogenic Ferroptosis via Activating Interferon-γ and Targeting Arachidonic Acid Metabolism.
    Liu Y; Niu R; Deng R; Song S; Wang Y; Zhang H
    J Am Chem Soc; 2023 Apr; 145(16):8965-8978. PubMed ID: 37058189
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ACSL4: a double-edged sword target in multiple myeloma, promotes cell proliferation and sensitizes cell to ferroptosis.
    Zhang J; Liu Y; Li Q; Zuo L; Zhang B; Zhao F; Fan F; Luo S; Hu Y; Sun C
    Carcinogenesis; 2023 May; 44(3):242-251. PubMed ID: 36999754
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SIAH2-Mediated Degradation of ACSL4 Inhibits the Anti-Tumor Activity of CD8+ T Cells in Hepatocellular Carcinoma.
    Shu F; Shi Y; Shan X; Zha W; Fan R; Xue W
    Crit Rev Eukaryot Gene Expr; 2024; 34(5):1-13. PubMed ID: 38842200
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High-fat diet impairs ferroptosis and promotes cancer invasiveness via downregulating tumor suppressor ACSL4 in lung adenocarcinoma.
    Zhang Y; Li S; Li F; Lv C; Yang QK
    Biol Direct; 2021 May; 16(1):10. PubMed ID: 34053456
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ACSL4 dictates ferroptosis sensitivity by shaping cellular lipid composition.
    Doll S; Proneth B; Tyurina YY; Panzilius E; Kobayashi S; Ingold I; Irmler M; Beckers J; Aichler M; Walch A; Prokisch H; Trümbach D; Mao G; Qu F; Bayir H; Füllekrug J; Scheel CH; Wurst W; Schick JA; Kagan VE; Angeli JP; Conrad M
    Nat Chem Biol; 2017 Jan; 13(1):91-98. PubMed ID: 27842070
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CD8
    Wang W; Green M; Choi JE; Gijón M; Kennedy PD; Johnson JK; Liao P; Lang X; Kryczek I; Sell A; Xia H; Zhou J; Li G; Li J; Li W; Wei S; Vatan L; Zhang H; Szeliga W; Gu W; Liu R; Lawrence TS; Lamb C; Tanno Y; Cieslik M; Stone E; Georgiou G; Chan TA; Chinnaiyan A; Zou W
    Nature; 2019 May; 569(7755):270-274. PubMed ID: 31043744
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ACSL4-mediated lipid rafts prevent membrane rupture and inhibit immunogenic cell death in melanoma.
    Zhao X; Zhao Z; Li B; Huan S; Li Z; Xie J; Liu G
    Cell Death Dis; 2024 Sep; 15(9):695. PubMed ID: 39343834
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of ACSL4 as a biomarker and contributor of ferroptosis.
    Yuan H; Li X; Zhang X; Kang R; Tang D
    Biochem Biophys Res Commun; 2016 Sep; 478(3):1338-43. PubMed ID: 27565726
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Acyl-CoA synthase ACSL4: an essential target in ferroptosis and fatty acid metabolism.
    Ding K; Liu C; Li L; Yang M; Jiang N; Luo S; Sun L
    Chin Med J (Engl); 2023 Nov; 136(21):2521-2537. PubMed ID: 37442770
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ACSL4 suppresses glioma cells proliferation via activating ferroptosis.
    Cheng J; Fan YQ; Liu BH; Zhou H; Wang JM; Chen QX
    Oncol Rep; 2020 Jan; 43(1):147-158. PubMed ID: 31789401
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MMD collaborates with ACSL4 and MBOAT7 to promote polyunsaturated phosphatidylinositol remodeling and susceptibility to ferroptosis.
    Phadnis VV; Snider J; Varadharajan V; Ramachandiran I; Deik AA; Lai ZW; Kunchok T; Eaton EN; Sebastiany C; Lyakisheva A; Vaccaro KD; Allen J; Yao Z; Wong V; Geng B; Weiskopf K; Clish CB; Brown JM; Stagljar I; Weinberg RA; Henry WS
    Cell Rep; 2023 Sep; 42(9):113023. PubMed ID: 37691145
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-chain acyl-CoA synthetase 4 participates in the formation of highly unsaturated fatty acid-containing phospholipids in murine macrophages.
    Kuwata H; Nakatani E; Shimbara-Matsubayashi S; Ishikawa F; Shibanuma M; Sasaki Y; Yoda E; Nakatani Y; Hara S
    Biochim Biophys Acta Mol Cell Biol Lipids; 2019 Nov; 1864(11):1606-1618. PubMed ID: 31376475
    [TBL] [Abstract][Full Text] [Related]  

  • 17. RB1-deficient prostate tumor growth and metastasis are vulnerable to ferroptosis induction via the E2F/ACSL4 axis.
    Wang ME; Chen J; Lu Y; Bawcom AR; Wu J; Ou J; Asara JM; Armstrong AJ; Wang Q; Li L; Wang Y; Huang J; Chen M
    J Clin Invest; 2023 May; 133(10):. PubMed ID: 36928314
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Living Cell-Target Responsive Accessibility Profiling Reveals Silibinin Targeting ACSL4 for Combating Ferroptosis.
    Yan W; Wang D; Wan N; Wang S; Shao C; Zhang H; Zhao Z; Lu W; Tian Y; Ye H; Hao H
    Anal Chem; 2022 Nov; 94(43):14820-14826. PubMed ID: 36260072
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ACSL4-dependent ferroptosis does not represent a tumor-suppressive mechanism but ACSL4 rather promotes liver cancer progression.
    Grube J; Woitok MM; Mohs A; Erschfeld S; Lynen C; Trautwein C; Otto T
    Cell Death Dis; 2022 Aug; 13(8):704. PubMed ID: 35963845
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Regulation of ROS in myeloid-derived suppressor cells through targeting fatty acid transport protein 2 enhanced anti-PD-L1 tumor immunotherapy.
    Adeshakin AO; Liu W; Adeshakin FO; Afolabi LO; Zhang M; Zhang G; Wang L; Li Z; Lin L; Cao Q; Yan D; Wan X
    Cell Immunol; 2021 Apr; 362():104286. PubMed ID: 33524739
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 45.